Search other companies ESG researched by sustainAX here
Dropdown Menu with Searchable Options

Bio-Works Technologies AB – ESG risk research and ESG rating

We at sustainAX have ESG risk researched and ESG risk rated Bio-Works Technologies AB and our clients can access the reseach on their Bloomberg terminals.

Bio-Works Technologies AB is in the materiality based sector of PHARMA, BIOTECH AND LIFE SCIENCES.

Our ESG risk research of Bio-Works Technologies AB

Our approach to ESG research is fundamental, that means that we have studied all relevant publications by Bio-Works Technologies AB and combined this with fundamental understanding of ESG challenges and risks of different activities and for the PHARMA, BIOTECH AND LIFE SCIENCES sector. This makes us well placed to estimate the ESG risks of Bio-Works Technologies AB. We have published a 33 pages ESG research report on Bio-Works Technologies AB with a conclusion highlighting the most important residual risks, a section suggesting how it should be integrated in investment decisions and a list of all the questions we think should be asked to Bio-Works Technologies AB.

More about our ESG risk research here:

AGGREGATED ESG RISK RATING* for Bio-Works Technologies AB:

40-60 of 100

Middle risk

Where 100 is the lowest ESG risk and 0 is the highest risk.

*The ESG, E, S and G risk rating ranges indicate to what degree Bio-Works Technologies AB has addressed and mitigated their material ESG risks according to the sustainAX materiality matrix. sustainAX’ clients have access to the exact ESG risk rating. 

**The weight in the aggregated ESG rating

Environmental RISK RATING* and WEIGHT** for Bio-Works Technologies AB:
0-20 of 100 Very High risk
Social RISK RATING* and WEIGHT** for Bio-Works Technologies AB:
40-60 of 100 – Middle risk
Governance RISK RATING* and WEIGHT** for Bio-Works Technologies AB:
60-80 of 100 – Low risk
About the company:

Bio-Works helps pharmaceutical companies and researchers achieve their purity and quality goals, from laboratory research to large-scale commercial production. WorkBeadsTM, our next-generation agarose-based product line, is used for the purification of proteins, peptides and other biomolecules the result is cleaner drugs and safer diagnostics. WorkBeads is delivered to Bio-Works' customers in bulk packaging, and since June 2022 in a turnkey format sold under the name GoBioTM.

Are you interested in the ESG research and ESG rating?

If you are interested in the ESG risk research and ESG risk rating of Bio-Works Technologies AB, contact us at sustainAX!

© Copyright SustainAX AB and, 2024. Please note that by accessing and using the SustainAX AB website, you are consenting to comply with our Terms of Use and acknowledging the acceptance of any inherent risks. The content provided on this site is available for your non-commercial, non-competitive use, specifically for the purposes of understanding companies’ environmental, social, and governance (ESG) risks. Should you wish to employ our information within a professional capacity, it is incumbent upon you to secure the appropriate licensing rights from us. Be aware that any form of unauthorised data extraction or the systematic electronic harvesting of our content is expressly forbidden.

Generated by MPG